Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol

Pharmacogenetics and Genomics

Volumn 17, Issue 11, 2007, Pages 941-949

  Chen, Lu ^a,c   Meyers, Deborah ^b   Javorsky, George ^b   Burstow, Darryl ^b   Lolekha, Pakorn ^b   Lucas, Margaret ^b   Semmler, Annalese B T ^a   Savarimuthu, Santiyagu M ^a   Fong, Kwun M ^a,c   Yang, Ian A ^a,c   Atherton, John ^a,d   Galbraith, Andrew J ^b   Parsonage, William A ^a,d   Molenaar, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Department of Cardiology ^*  (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Beta adrenergic receptor blocking drugs; Beta1 adrenergic and beta2 adrenergic receptors; Cardiomyopathy; Carvedilol; Genetic polymorphisms; Heart failure

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; GLYCINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TREATMENT DURATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHYSIOLOGY; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-1; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 37349022820     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282ef7354     Document Type: Article

References (39)

1. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558-569.
2. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349:375-380.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
4. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
5. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101:378-384.
6. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
7. Molenaar P, Parsonage WA. Fundamental considerations of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 2005; 26:368-375.
8. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96:2197-2205.
9. O'Keefe JH Jr, Magalski A, Stevens TL, Bresnahan DR Jr, Alaswad K, Krueger SK, et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol 2000; 7:3-7.
10. Parsonage WA, Galbraith A, Scalia GM. Dramatic effect of cardvedilol in patients treated for left ventricular dysfunction-intermediate follow-up. Heart Lung and Circulation 2001; 10:A114.
11. Van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 1998; 32 (Suppl 1):S31-S35.
12. 1-adrenoceptor: identification and rapid screening assay. Lancet 1999; 353:897.
13. 1-adrenergic receptor. J Biol Chem 1999;274:12670-12674.
14. Brodde OE. β-Adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 2007; 374:361-372.
15. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268:23116-23121.
16. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51:651-690.
17. 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-1305.
18. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103:11288-11293.
19. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
20. 1-adrenoceptors in human heart. Cardiovasc Res 2006;69:128-139.
21. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. β-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003;13:379-382.
22. De Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, Foucher-Hossein C, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005;15:137-142.
23. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to update the 1997 guidelines for the clinical application of echocardiography). J Am Soc Echocardiogr 2003; 16:1091-1110.
24. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-1552.
25. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004; 44:878-886.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
27. Molenaar P, Rabnott G, Yang I, Fong KM, Savarimuthu SM, Li L, et al. Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49Gly and Gly389Arg beta1-adrenergic receptor polymorphisms in human right atrium in vitro. J Am Coll Cardiol 2002; 40:1275-1282.
28. 2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn-Schmiedebergs Arch Pharmacol 2007; 375:11-28.
29. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators. Circulation 1996; 94:2807-2816.
30. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36:2072-2080.
31. Hole T, Froland G, Gullestad L, Offstad J, Skjaerpe T. Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure. Echocardiography 2004; 21:215-223.
32. 1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet Genomics 2005; 15:227-234.
33. 1-adrenoceptors. Br J Pharmacol 2004; 142:51-56.
34. 2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999;99:65-72.
35. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1667.
36. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study group. Circulation 2002; 106:2194- 2199.
37. 1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005; 78:221-231.
38. 1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21:1853-1858.
39. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534-1539.